ONCOCHECK
Financiado
A simple blood test for prognosis and monitoring of patients undergoing cancer t...
The objective of the ONCOCHECK project is to bring to the healthcare market a unique solution for cancer prognosis and monitoring which is a simple and inexpensive (<€200/test) blood test that will allow oncologists the prediction...
The objective of the ONCOCHECK project is to bring to the healthcare market a unique solution for cancer prognosis and monitoring which is a simple and inexpensive (<€200/test) blood test that will allow oncologists the prediction and evaluation of disease progression (monitoring) in patients affected by the great majority of cancers, with no distinction between haematological or solid tumors. The ONCOCHECK test is based on the determination of telomere length in peripheral blood, which is a blood cell marker that has been identified in the majority of cancers. The great advantage of the ONCOCHECK tests over any competing blood tests based on cancer tumor markers is that ONCOCHECK will serve for monitoring virtually all types of cancer, while competing tumor marker based solutions are useful only for a specific cancer/tumor. Therefore, Life Length´s test will offer a universal solution for cancer monitoring, with no competitors offering a similar approach.
Considering the more than 35 million of people affected by cancer all over the world and that ONCOCHECK will serve for monitoring all cancer types, the business opportunity seems unquestionable. Through the ONCOCHECK project, we seek positioning our company as a leading player in the Advanced Next Generation Cancer Diagnostic Market, which was already estimated globally to generate €7.1 billion in sales in 2015 and is forecast to exceed €13.1 billion by 2020. The main market drivers are the development of less invasive and less costly tools that can contribute to a more efficient, more frequent and sustainable management of cancer. In line with this, the ONCOCHECK project will offer oncologist a cost effective solution to the current challenges in regular cancer monitoring and management.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2016-12-16
Fecha Fin: 2018-12-31
Fecha Fin: 2018-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
LIFE LENGTH
La prestacion y comercializacion, directa o a traves de terceros con quienes a tal efecto contrate, de servicios de mediacion de la longitud...
Perfil tecnológico
TRL
3-4
558K
Perfil tecnológico
TRL
3-4
558K